All In Biotech

Drug Trial Radar · NCT06240546

First-in-Human Study of LPM6690176 in Patients With Advanced Solid Tumors.

A Phase I, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LPM6690176 Capsules in Patients With Advanced Solid Tumors.

Last checked: Nov 19, 2026Latest source record: Mar 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

102

Planned (sponsor's estimate)

Start

Mar 12, 2024

Primary completion

Feb 2026

Study completion Feb 2027

Sponsor

Lead sponsor
Luye Pharma Group Ltd.Industry
Sponsor type
Industry
First posted
Feb 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a phase 1, first-in-human, open-label, dose-escalation and dose-expansion study designed to evaluate the safety and tolerability, pharmacokinetics characteristics and preliminary anti-tumor activity of LPM6690176 capsules in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

  • LPM6690176Drug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of dose-limiting toxicities (DLTs)Time frame: From the first dose of study drug treatment through Cycle 1 (28 days)
  2. maximum tolerated dose (MTD) of LPM6690176Time frame: From the first dose of study drug treatment through Cycle 1 (28 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.